Back to results
US 11,542,486 B2Granted
Human kynureninase enzyme variants having improved pharmacological properties
AssigneeBoard of Regents, The University of Texas System
InventorsGeorge Georgiou, Everett Stone, John Blazeck
Life of this patent
Estimating the term…
Abstract
Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
Claims13
An isolated, modified human kynureninase enzyme, said modified enzyme comprising a mutation set relative to native human kynureninase (see SEQ ID NO:
- 1), wherein the mutation set is selected from the group consisting of the following mutation sets:
- (a) A99I, G112A, F306Y, I331N, I405L, S408N and A436T;
- (b) A99I, G112A, K191E, F306Y, A381S, I405L, S408N and A436T;
- (c) Q14R, A99I, G112A, M189I, H230Y, F306Y, I331N, I405L, S408N and A436T;
- (d) T138S, H224N, F225Y, F306W, N333T, S408N and A436T;
- (e) N67D, L72N, E103Q, F225Y, I331V, S408N and A436T;
- (f) N67D, A136S, T138S, F225Y, S408N and A436T;
- and (g) A99S, A136G, L137T, F306L and A436T.
5 more elements
Dependencies are inferred from the claim text.